<DOC>
	<DOCNO>NCT00452374</DOCNO>
	<brief_summary>Primary Objectives : 1 . Determine maximum tolerate dose ( MTD ) dose-limiting toxicity ( DLT ) oxaliplatin combination fludarabine , Ara-C rituximab patient Richter 's transformation , prolymphocytic leukemia ( PLL ) , refractory/relapsed B-cell chronic lymphocytic leukemia ( CLL ) . 2 . Assess complete response ( CR ) partial response ( PR ) rate combination therapy oxaliplatin , fludarabine , Ara-C rituximab patient Richter 's transformation , PLL refractory/relapsed B-cell CLL . 3 . Determine safety toxicity profile combination therapy oxaliplatin , fludarabine , Ara-C rituximab patient Richter 's transformation , PLL refractory/relapsed B-cell CLL . Secondary Objectives : 1 . Determine duration response , failure-free survival , overall survival . 2 . Determine incidence infection ( bacterial , fungal , viral ) patient Richter 's transformation , prolymphocytic leukemia refractory/relapsed B-cell CLL treat rituximab , oxaliplatin , fludarabine Ara-C ; monitor immune parameter T cell count immunoglobulin level ; monitor Epstein-Barr virus ( EBV ) status . 3 . Characterize pharmacodynamics oxaliplatin leukemia cell respect total adduct formation , cross-link formation excision deoxyribonucleic acid ( DNA ) responses . Compare parameter cell patient treatment oxaliplatin combination fludarabine Ara-C .</brief_summary>
	<brief_title>Oxaliplatin , Fludarabine , Cytarabine Rituximab Richter 's Syndrome , Refractory CLL PLL</brief_title>
	<detailed_description>Oxaliplatin , fludarabine , cytarabine rituximab anticancer drug . Oxaliplatin platinum compound show effective fighting cancer . Oxaliplatin third generation platinum compound high activity less toxicity colon cancer tumor compare platinum compound , cisplatin . Oxaliplatin show activity patient relapse refractory non-Hodgkin 's lymphoma . Before treatment start , complete physical exam routine blood test ( 2 teaspoon ) . A bone marrow sample collect . To collect bone marrow sample , area hip chest bone numb anesthetic small amount bone marrow withdrawn large needle . Women able child must negative blood urine pregnancy test . This research study two part , Phase I part Phase II part . You receive least 1 cycle therapy . Oxaliplatin give needle vein ( call IV ) 4 day ( Days 1 4 ) . Rituximab give IV Day 3 first cycle Day 1 every cycle . One day first dose oxaliplatin rituximab ( Day 2 ) , fludarabine cytarabine give IV two day ( Days 2 3 ) . Peg-filgrastim give subcutaneously ( needle skin ) Day 6 . Other IV fluid saline give treatment day keep dehydrate , mean daily visit may take eight hour . The combination repeat cycle ( every 28 day ) total 6 cycle . During Phase I II phase study , researcher test different dose level study drug combination . Three patient enrol dose level . Each time dose level raise , occur patient monitor 28 day . Individual patient experience serious drug-related side effect second cycle may receive next high dose level follow treatment cycle . Drugs give dose rituximab low risk side effect . If side effect occur rituximab treatment , rituximab may stop side effect go away restart . This may make time outpatient area longer . The first treatment cycle give M. D. Anderson . Depending response treatment , 5 cycle perform either M. D. Anderson home regular physician . After 3 cycle treatment , check M. D. Anderson see disease respond treatment . If disease respond 3 cycle therapy , may continue receive therapy 3 cycle . If disease responding , take study doctor discus treatment option . Once best safe dose drug combination find Phase I portion study , next group participant enter study take part Phase II portion study . The goal part study look effect drug combination patient refractory CLL , prolymphocytic leukemia Richter 's transformation . The dose level combination one find Phase I part study . The dose level four drug use throughout Phase II portion study , unless intolerable side effect occur . In case , dose may lower treatment may stop . You take study disease get bad . During treatment cycle , blood sample ( 1 teaspoon ) take every 1-2 week . Bone marrow biopsy do end 3rd 6th chemotherapy cycle . After last cycle treatment complete , blood drawn ( 2 teaspoon ) every 3 month long remission , routine testing . This investigational study . The FDA authorize use drug research , give purpose . All drug commercially available type treatment . Oxaliplatin free charge study . You and/or insurance company responsible cost drug use study . Patients enrol M. D. Anderson , University California , San Diego , Dana-Farber Cancer Institute . Up 52 patient take part multicenter study . The estimated number patient treat M. D. Anderson 52 .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Leukemia , Prolymphocytic</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>1 . Histologically cytologically confirm Richter 's transformation , fludarabinerefractory chronic lymphocytic leukemia prolymphocytic leukemia . 2 . Patients must 18 year age old . 3 . Patients must performance status 02 ( Zubrod scale ) . 4 . Patients must adequate renal function ( serum creatinine equal 2mg/dL creatinine clearance great 30mL/min ) , unless renal dysfunction consider due organ infiltration disease . 5 . Patients must adequate hepatic function ( bilirubin less equal 2.0 mg/dl ; Serum glutamic oxaloacetic transaminase ( SGOT ) serum glutamic pyruvic transaminase ( SGPT ) less equal 3 time upper limit normal ( ULN ) reference lab unless consider due leukemia congenital hemolytic disorder ( bilirubin ) . 6 . Female patient childbearing potential ( include &lt; 1 year postmenopausal ) male patient must agree use contraception . 7 . Patients must sign informed consent indicate aware investigational nature study keep policy hospital . 8 . Patients must platelet count great equal 20,000 , unless due disease involvement , autoimmune disorder . 1 . Untreated uncontrolled lifethreatening infection . 2 . Oxaliplatin , fludarabine , cytarabine rituximab intolerance . 3 . Pregnancy lactation . 4 . Chemotherapy and/or radiation therapy within 4 week . 5 . Medical condition , include mental illness substance abuse , deem Investigator likely interfere patient 's ability sign inform consent , cooperate participate study , interfere interpretation result .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>B-cell chronic lymphocytic leukemia</keyword>
	<keyword>Chronic Lymphocytic Leukemia</keyword>
	<keyword>CLL</keyword>
	<keyword>Prolymphocytic Leukemia</keyword>
	<keyword>PLL</keyword>
	<keyword>Richter 's Transformation</keyword>
	<keyword>High-grade non-Hodgkin 's lymphoma</keyword>
	<keyword>Hodgkin 's disease</keyword>
	<keyword>Acute leukemia</keyword>
	<keyword>Small lymphocytic lymphoma</keyword>
	<keyword>Oxaliplatin</keyword>
	<keyword>Eloxatin</keyword>
	<keyword>Fludarabine</keyword>
	<keyword>Cytarabine</keyword>
	<keyword>Ara-C</keyword>
	<keyword>Cytosar</keyword>
	<keyword>DepoCyt</keyword>
	<keyword>Cytosine arabinosine hydrochloride</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Rituxan</keyword>
</DOC>